Repeated B cell depletion in treatment of refractory systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 65, Issue 7, 2006, Pages 942-945

  Ng, K P ^a   Leandro, M J ^a   Edwards, J C ^a   Ehrenstein, M R ^a   Cambridge, G ^a   Isenberg, D A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Centre for Rheumatology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; STEROID;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HERPES ZOSTER; HUMAN; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; RELAPSE; SERUM SICKNESS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; B-LYMPHOCYTES; COMPLEMENT C3; CYCLOPHOSPHAMIDE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RECURRENCE;

EID: 33745714540     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.044487     Document Type: Article

References (11)

1. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
2. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B cell depletion in the treatment of patients with systemic lupus erythematosus - a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5.
3. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend U, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
4. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
5. Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erytematosus in a patient with antibodies against rituximab. Rheumatology (Oxford), 2005;44:561-2.
6. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
7. Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003;12:779-82.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
9. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab. Blood 2004;104:2635-42.
10. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7.
11. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50.